Fampridin: Gute Krankengymnastik reicht aus – Kontra

Dalfampridine oder Fampridin (Famypra^®) ist eine retardierte Variante des 4-Aminopyridin (4-AP). Es ist seit 2011 zur Behandlung der Gangstörung bei Multipler Sklerose (MS) in Deutschland zugelassen. Die Zulassung beruht auf 2 Phase-III-Studien, die verblindet und placebokontrolliert bei über 200 Patienten mit gesicherter MS durchgeführt wurden [1] [2].

• Literatur

• 1 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502
• 2 Goodman AD, Brown TR, Krupp LB et al. Sustained release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738
• 3 Ramagopalan SV, Seminog O, Goldacre R et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727-739
• 4 Weinshenker BG, Rice GP, Noseworthy JH et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057-1060
• 5 Kjølhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training: a systematic review. Mult Scler 2012; 18: 1215-1228
• 6 Espejo C, Montalban X. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clin Immunol 2012; 142: 84-92
• 7 Judge SI, Lee JM, Bever Jr CT et al. Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev 2006; 43: 111-122
• 8 Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981; 313: 301-315
• 9 Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283: 570-572
• 10 Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997; 77: 553-562
• 11 Goodman TR, Brown JA, Cohen LB et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134-1141
• 12 Goodman AD, Cohen JA, Cross A et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13: 357-368
• 13 Chwieduk CM, Keating GM. Dalfampridine extended release: in multiple sclerosis. CNS Drugs 2010; 24: 883-891
• 14 Kachuck NJ. Sustained release oral fampridine in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009; 10: 2025-2035
• 15 Hupperts R, Lycke J, Short C et al. Prolonged-release fampridine and walking and balance in MS: randomized controlled MOBILE trial. Mult Scler 2015; [Epub ahead of print]
• 16 Goodman AD, Bethoux F, Brown TR et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Mult Scler J 2015; [Epub ahead of print]